Research
Adherence
GLP-1 monotherapy (liraglutide, semaglutide) is associated with high discontinuation rates due to gastrointestinal side effects, limiting long-term adherence.
Be aware that GLP-1 monotherapy can cause significant gastrointestinal side effects, leading to high discontinuation rates. Discuss titration strategies with your provider to minimize these effects.
GoodQualifiesHIGH confidence
GLP-1R mimetics are often discontinued within 24-months, owing to gastrointestinal side-effects, meaning long-term application of these agents in obesity is questioned.
Why this rating
Based on clinical trial data and real-world usage statistics cited in the paper.
Source
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Ryan A. Lafferty et al. · Expert Opinion on Pharmacotherapy · 2023
narrative_reviewCited 42×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →